Compliance Intelligence, Inspection Readiness, Regulatory Guide, Platform Integration, Industry Landscape, Contract Manufacturing, Clinical Trials, Regulatory Intelligence, Regulatory Submissions, Pharmacovigilance, Preclinical & GLP, Cross-Domain Intelligence, Manufacturing Compliance, GMP, AI in QMS, Quality Operations, Compliance Benchmarks Harsh Shah Compliance Intelligence, Inspection Readiness, Regulatory Guide, Platform Integration, Industry Landscape, Contract Manufacturing, Clinical Trials, Regulatory Intelligence, Regulatory Submissions, Pharmacovigilance, Preclinical & GLP, Cross-Domain Intelligence, Manufacturing Compliance, GMP, AI in QMS, Quality Operations, Compliance Benchmarks Harsh Shah

Why drugs fail FDA review on quality, not science 

FDA released 202 Complete Response Letters in July 2025. Manufacturing and quality deficiencies appeared in 74% of them. The clinical data was rarely the problem.
Read More
Compliance Intelligence, Inspection Readiness, Regulatory Guide, Platform Integration, Industry Landscape, Contract Manufacturing, Clinical Trials, Regulatory Intelligence, Regulatory Submissions, Pharmacovigilance, Preclinical & GLP, Cross-Domain Intelligence, Manufacturing Compliance, GMP, AI in QMS, Quality Operations, Compliance Benchmarks Harsh Shah Compliance Intelligence, Inspection Readiness, Regulatory Guide, Platform Integration, Industry Landscape, Contract Manufacturing, Clinical Trials, Regulatory Intelligence, Regulatory Submissions, Pharmacovigilance, Preclinical & GLP, Cross-Domain Intelligence, Manufacturing Compliance, GMP, AI in QMS, Quality Operations, Compliance Benchmarks Harsh Shah

Deviation investigation cost and CAPA closure benchmarks: what the numbers actually say 

Same 21 CFR rules at four people as at forty. A clinical-stage biotech carries enterprise regulatory requirements on startup resources, which is why the ROI math for AI in QMS looks nothing like the enterprise pharma case.
Read More